Assembly Biosciences (NASDAQ:ASMB) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.87) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.01) by $0.14, MarketWatch Earnings reports. Assembly Biosciences had a negative return on equity of 66.34% and a negative net margin of 457.20%. The company had revenue of $4.29 million for the quarter, compared to analysts’ expectations of $3.21 million.
Shares of ASMB traded down $2.19 during mid-day trading on Friday, hitting $23.40. 193,600 shares of the stock were exchanged, compared to its average volume of 209,032. The stock has a market capitalization of $559.82 million, a price-to-earnings ratio of -9.71 and a beta of 1.43. Assembly Biosciences has a 52-week low of $20.61 and a 52-week high of $67.36.
Several brokerages have recently issued reports on ASMB. BidaskClub cut Assembly Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, July 13th. Robert W. Baird began coverage on Assembly Biosciences in a report on Wednesday, August 8th. They set an “outperform” rating and a $74.00 price objective on the stock. Zacks Investment Research cut Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Monday, August 13th. ValuEngine cut Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 3rd. Finally, B. Riley raised Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 price objective on the stock in a report on Monday, October 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. Assembly Biosciences has an average rating of “Hold” and a consensus price target of $62.60.
COPYRIGHT VIOLATION WARNING: This story was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.wkrb13.com/2018/11/10/assembly-biosciences-asmb-issues-earnings-results-beats-estimates-by-0-14-eps.html.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Recommended Story: How to Invest in an Index Fund
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.